Receive our newsletter – data, insights and analysis delivered to you
July 13, 2009

J&J Completes Deal for Cougar Biotech

Johnson & Johnson (J&J) has announced that it has successfully completed the acquisition of Cougar Biotechnology, a development-stage biopharmaceutical company with a focus on oncology. The acquisition was completed through a "short-form" merger, conducted without a vote or meetin

By cms admin

Johnson & Johnson (J&J) has announced that it has successfully completed the acquisition of Cougar Biotechnology, a development-stage biopharmaceutical company with a focus on oncology.

The acquisition was completed through a “short-form” merger, conducted without a vote or meeting of Cougar Biotechnology’s remaining shareholders.

J&J tendered approximately 20,148,930 shares, representing approximately 95.9% of Cougar Biotechnology’s outstanding common stock.

Cougar Biotechnology will now operate as a wholly owned subsidiary of J&J and will work with Ortho Biotech Oncology Research & Development, a unit of Centocor Research & Development, Inc, a J&J company.

Cougar Biotechnology is currently conducting two Phase III trials for abiraterone acetate, an innovative late-stage compound for the treatment of prostate cancer.

The first Phase III trial is testing abiraterone acetate in patients with metastatic, castration-resistant prostate cancer who have progressed after docetaxel-based chemotherapy has failed.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Ortho Biotech Oncology Research & Development global therapeutic head William N Hait said that with the acquisition of Cougar Biotechnology the company has strengthened its position in the global oncology market and its efforts to provide a meaningful difference in the lives of millions of patients worldwide.

“Abiraterone acetate now becomes one of many new treatments we are developing, which we hope will change the course of cancer treatment by targeting cancer cells and the tumour microenvironment,” Hait said.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU